newsfilter
← Latest News
PR Newswire·

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome...